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Abstract. The opioid antagonist effects of systemically 
administered nor-binaltorphimine (nor-BNI) were evalu- 
ated against the kappa agonists CI-977, U69,593, 
U50,488, ethylketocyclazocine (EKC), Mr2034 and 
bremazocine, the mu agonist morphine and the alkaloid 
delta agonist BW-373U86 in the acetic acid-induced 
writhing assay in mice. All eight agonists completely and 
dose-dependently inhibited writhing. Antagonism of CI- 
977 was apparent 1 h after administration of 32 mg/kg 
nor-BNI, peaking after 4 h and was maintained for at least 
4 weeks; no antagonist effects of nor-BNI were apparent 
after 8 weeks. Nor-BNI (32 mg/kg) caused little or no 
antagonism of morphine or BW-373U86 at i h and none 
at 24 h after nor-BNI administration. Subsequently, dose- 
effect curves for CI-977, U50,488, U69,593, EKC, Mr2034 
and bremazocine were determined 24 h after pretreatment 
with 3.2, 10 and 32 mg/kg nor-BNI. Pretreatment with 
3.2 mg/kg nor-BNI produced significant antagonism of all 
six kappa agonists, suggesting that their antinociceptive 
effects were mediated at least in part by nor-BNI-sensitive 
kappa receptors. At higher doses, nor-BNI dose-depend- 
ently shifted the agonist dose-effect curves of CI-977, 
U50,488, U69,593 and bremazocine, but not those of EKC 
and Mr2034, suggesting that the latter compounds may be 
producing effects via nor-BNI-insensitive receptors. Mu 
receptor involvement was demonstrated following a 24 h 
pretreatment with 32 mg/kg/?-FNA in combination with 
nor-BNI, which significantly increased the degree of an- 
tagonism of Mr2034 and EKC from that seen with nor- 
BNI alone. Hence, SC administered nor-BNI selectively 
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antagonized agonist activity mediated through kappa- 
opioid receptors without differentiating between kappa 
subtypes. Nor-BNI also enabled the mu agonist activity of 
proposed kappa agonists to be measured. 
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There is much experimental evidence supporting the 
premise that opioid effects are mediated by at least three 
opioid receptor types: mu and kappa (Martin et al 1976) 
and delta (Lord et al. 1977). Subsequent studies have high- 
lighted some heterogeneity in the receptors within these 
opioid types, and further subdivisions of the mu (Paster- 
nak 1986; Rothman et al. 1991), kappa (Zukin et al. 1988; 
Clark et al. 1989; Devlin and Shoemaker 1990; Rothman 
et al. 1990) and delta (Jiang et al. 1991; Sofuoglu et al. 
1991) receptor types have been proposed. 
The development of selective opioid antagonists has 
played a critical role in distinguishing among receptor 
types. For  instance, /~-funaltrexamine (Portoghese et al. 
1980) and naltrindole (Portoghese et al. 1988) have been 
characterized as mu- and delta- receptor antagonists re- 
spectively. Nor-binaltorphimine (nor-BNI) has been pro- 
posed as a kappa-selective antagonist (Portoghese et al. 
1987; Takemori et al. 1988a). It has since been demon- 
strated that nor-BNI is a selective, systemically active and 
reversible kappa antagonist with a slow onset and a long 
duration of action of up to 8 weeks (Endoh et al. 1992; 
Horan et al. 1992; Jones and Holtzman 1992; Butelman 
et al. 1993). 
Kappa receptors are of special interest as they mediate 
antinociceptive effects without the side effects of respira- 
tory depression and high abuse potential that limit the 
clinical utility of mu agonists. Kappa receptors have been 
implicated as important mediators in the control of water 
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balance (Cooper and Sanger 1984), food intake (Cooper 
et al. 1985), antinociception (Schmauss and Yaksh 1984), 
discriminative stimulus effects (e.g. Hein et al. 1981) and 
sedation (Martin et al. 1976). The use of in vitro tech- 
niques that employ radio-labeled ligands in rodent brain 
homogenates has identified receptor subtypes to which 
kappa-selective ligands bind with differential affinity, en- 
abling some preliminary characterization of kappa recep- 
tor subtypes (Zukin et al. 1988; Clark et al. t989; Devlin 
and Shoemaker 1990; Rothman et al. 1990). The first 
physiological evidence for kappa  receptor heterogeneity 
was demonstrated using the opioid antagonist 
quadazocine (WIN 44441-3), which antagonized the ef- 
fects of tifluadom and ethylketocyctazocine (EKC) on 
plasma corticosterone and TSH levels, but not those of 
Mr2034 or U50,488 (Iyengar et al. 1986). Recent in vivo 
work in mice reported differential antagonism of kappa 
agonists using ( - ) -UPHIT,  a selective, non-equilibrium 
kappa antagonist, and suggested that this was due to 
heterogeneity among kappa receptors (Horan et al. 1991). 
Several studies have indicated that nor-BNI may also 
be useful in differentiating between kappa agonists, perhaps 
on the basis of kappa receptor subtypes. Some in vitro 
binding studies indicate that nor-BNI differs in its affinity 
for various kappa receptor subtypes (Rothman et al. 1988; 
Clark et al. 1989), and in the guinea pig ileum assay, nor- 
BNI was shown to be a more potent antagonist of U50,488 
than of EKC (Portoghese et al. 1987). In vivo work examin- 
ing the effect of systemic nor-BNI administration on diur- 
esis produced by kappa agonists in rats showed that nor- 
BNI was a more effective antagonist of both U50,488 and 
bremazocine-induced diuresis than of EKC-induced diur- 
esis (Takemori et al. 1988b). Recent studies in our laborat- 
ory involving rhesus monkeys in the warm water tail- 
withdrawal assay showed that systemically administered 
nor-BNI antagonized the antinociceptive effects of U69,593 
and U50,488 but had no effect on CI-977, bremazocine, 
Mr2033 or EKC (Butelman et al. 1993). Studies where nor- 
BNI was administered to mice are somewhat ambiguous 
with respect to whether or not kappa agonists are differen- 
tially antagonized by nor-BNI (Takemori et al. 1988a; 
Horan et al. 1992). These inconsistent findings may be 
a reflection of differences in kappa opioid pharmacology in 
mice relative to other species (particularly primates), or of 
procedural differences across studies. To date, no one study 
has set out to evaluate the antagonist effects of nor-BNI 
across a range of kappa agonists in mice. 
Accordingly, the purpose of the present study was to 
conduct a detailed examination of the potency with which 
nor-BNI antagonizes a wide range of kappa  agonists, and 
thus explore the hypothesis that kappa  agonists will differ 
in their sensitivity to nor-BNI when administered to mice, 
as has been reported in other species. If the results support  
this hypothesis, the existence of a subset(s) of kappa recep- 
tors at which nor-BNI has less affinity may be indicated. 
Alternatively, it may be possible to demonstrate that some 
kappa agonists have activity at non-kappa  sites under 
these experimental conditions. This study will endeavor to 
discern which if either of these alternatives provides the 
best explanation. 
Initially, the time course of the kappa,  mu and delta 
opioid antagonist effects of systemically administered nor- 
BNI was evaluated against the highly selective kappa 
agonist CI-977 (Hunter et al. 1990), the mu agonist mor- 
phine (Martin et al. 1976) and the delta agonist, BW- 
373U86 (Comer 1992; Chang et al. t994). Subsequently, 
the present study examined the ability of systemically 
administered nor-BNI to selectively antagonize the effects 
of a series of kappa agonists including the arylacetamides 
CI-977, U50,488 (Von Voigtlander etal.  1982) and 
U69,593 (Lahti et al. 1985), and the benzomorphans EKC 
(Martin et al. 1976), bremazocine (Romer et al. 1980) and 
Mr2034 (Merz et al. 1975). A role for mu receptors in 
mediating the antinociceptive effects of some kappa  agon- 
ists was evaluated using the selective and irreversible mu 
antagonist/~-funaltrexamine (//-FNA; Ward et al. 1982). 
Materials and methods 
Animals. Male NIH mice (18-32g, Harlan Sprague-Dawley, In- 
dianapolis, Ind.) were housed 8-12 per cage at approximately 22 °C 
on a 12-h light/dark cycle. Food and water were available ad libitum 
until testing. Each animal was used only once. 
Test ofantinociception. The acetic acid-induced writhing assay (Ko- 
ster et al. 1959), as modified for use in this laboratory (Comer 1992), 
was used to determine the degree of antinociception. Briefly, mice 
received an IP injection of 0.6% acetic acid (0.4 ml/animal) and were 
placed in individual Plexiglas boxes (18 × 28 x 13 cm) for observa- 
tion. Five minutes after the acetic acid injection was given, a 5-rain 
observation period was initiated during which time the number of 
writhes, typically a wave of contraction of the abdominal musculat- 
ure followed by extension of the hind legs, was recorded. Vehicle or 
test drugs were administered at various times prior to the adminis- 
tration of acetic acid, as detailed below. 
Effects ofnor-BNI alone. The agonist effects of sterile water, 10 and 
32 mg/kg nor-BNI were tested by administering sterile water or 
nor-BNI SC at 5, 10, 15, 30, 45, 60, 75 and 90 rain as welt as 24 h 
prior to the administration of acid. Higher doses of nor-BNI were 
not investigated because it was found that they caused local irrita- 
tion for several hours, with subsequent visible tissue damage at the 
site of injection. 
Time course of the antagonist effects of nor-BNI. Since 32 mg/kg 
nor-BNI was the highest dose that could be safely administered, the 
next phase of experiments examined the time course of the kappa, 
mu and delta antagonist effects of 32 mg/kg nor-BNI. This was 
evaluated against CI-977 (0.0t-1.0 mg/kg), morphine 
(0.1-3.2 mg/kg) and BW-373U86 (0.32-32 mg/kg), respectively, with 
baseline agonist dose-effect curves determined by administering 
each agonist 15 rain prior to the administration of acetic acid. The 
dose-effect curves for CI-977, morphine and BW-373U86 were then 
determined by administering the agonist 1 h and 24 h after the 
administration of 32 mg/kg nor-BNI. A more complete time course 
of antagonism was obtained with CI-977 by determining the CI-977 
dose-effect curve 4 hr, 2, 4, 7, 28 and 56 days after nor-BNI. Each 
observation point was determined using a different group of mice. 
Selectivity of kappa antagonist effects of nor-BNI. Since the time 
course evaluation indicated that the peak antagonist effects of nor- 
BNI were sustained from 4 h to 4 weeks after its administration, 
subsequent studies employed a 24 h pretreatment time. The sensitiv- 
ity of kappa agonists to antagonism by nor-BNI was evaluated using 
the following kappa agonists; CI-977 (0.01-1.0 mg/kg), U50,488 
(1.0-100 mg/kg), U69,593 (0.I-10 mg/kg), EKC (0.032-1.0 mg/kg), 
bremazocine (0.0032-3.2 mg/kg) and Mr2034 (0.0032-0.32 mg/kg). 
Baseline dose-effect curves for each agonist were determined as 
described above. Dose-effect curves for each agonist were then 
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determined again 24 h after pretreatment with 3.2, 10 and 32 mg/kg 
nor-BNI. 
32 mg/kg) were no different than the effects of  sterile water 
on acetic acid-induced writhing (P > 0.05). 
Antagonist effects of fl-funaltrexamine. Since nor-BNI did not pro- 
duce a dose-dependent antagonism of EKC or Mr2034, we evalu- 
ated the possible role of mu receptors in the antinociceptive effects of 
these agonists using the mu-selective and irreversible antagonist 
fl-FNA. We then compared the agonist dose-effect curves for EKC 
and Mr2034 under the following four conditions: 1) agonist alone, 
2) 24 h after pretreatment with 32 mg/kg nor-BNI, 3) 24 h after 
pretreatment with 32 mg/kg fl-FNA, and 4) 24 h after pretreatment 
with both 32 mg/kg fl-FNA and 32 mg/kg nor-BNI. By way of 
comparison, the antagonist effects of nor-BNI, fi-FNA and the 
fi-FNA/nor-BNI combination were evaluated against CI-977, 
U69,593, morphine and BW-373U86. The 32 mg/kg dose and 24-h 
pretreatment time for fl-FNA were used on the basis of preliminary 
experiments, indicating that under these conditions, fl-FNA did not 
produce agonist effects but did antagonize the effects of morphine 
(Ward et al. 1982). 
Chemicals. The compounds used in this study were: nor-BNI 
(B. de Costa, NIDDK, National Institutes of Health, Bethesda, Md.), 
fl-FNA (D. Zimmerman, Eli Lilly, Indianapolis, Ind.), CI-977 
(Parke-Davis, Ann Arbor, Mich.), U50,488 and U69,593 (Upjohn, 
Kalamazoo, Mich.), EKC (National Institute on Drug Abuse, 
Rockville, Md), bremazocine (Sandoz, Basel, Switzerland), 
Mr2034 (B0ehringer Ingelheim, Ingelheim am Rhein, Germany), 
morphine sulfate (Mallinkrodt, St Louis, Mo.) and BW-373U86 
(( +_ )-4-( (R*)-c~-((2S*5R*)-4-AllyI-2,5-dimethyl-l-piperazinal)-3-hy- 
droxybenzyl)-N,N-diethytbenzamide dihydrochloride; Burroughs 
Wellcome, Research Triangle Park, N.C.). All compounds were 
dissolved in sterile water and were administered in volumes of 
0.01ml/g SC. CI-977, U50,488, U69,593, bremazocine, EKC, 
Mr2034, morphine and BW-373U86 were all administered 15 min 
prior to acid in the present study on the basis of preliminary studies 
indicating that all eight compounds produced peak effects at this 
pretreatment time. Glacial acetic acid was purchased from Fisher 
Scientific Co., Fair Lawn, N.J. and the 0.6% solution was made 
using sterile water. 
Data analysis. Each treatment group consisted of six mice, and each 
mouse was used for only one treatment. The control number of 
writhes per mouse was defined as the mean number of writhes per 
mouse when a SC injection of sterile water was given 15 min prior to 
the acetic acid injection. The value of the control was found to vary 
somewhat between batches of mice and thus was routinely redeter- 
mined for each new batch (generally once a week). For treatment 
groups, the number of writhes for each mouse was expressed as 
percent of the control number of writhes per mouse. The percent 
control values for the mice in the treatment group were then aver- 
aged and the SEM calculated. Aso values and 95 % confidence limits 
were determined for each agonist administered alone and after 
pretreatment with nor-BNI according to the method of Tallarida 
and Murray (1981. procedure 8), with the Aso defined as the dose of 
agonist reducing writhing to 50% of control. Dose-effect curves were 
considered to be significantly different when the range of values 
contained within the 95% confidence limits did not overlap. The 
time course of the effects of nor-BNI when administered alone was 
analyzed using analysis of variance with two between subjects vari- 
ables; dose and time. 
R e s u l t s  
Control values 
Mean control  values across batches of  mice ranged f rom 
11.3 + 2.6 to 16.3 + 1.7 writhes per mouse. The I P  admin- 
istration of 0.4 ml sterile water alone did not  induce writh- 
ing. Fur thermore,  the effects of  no r -BNI  alone (10 and 
Agonist effects 
The dose-effect curves for the kappa  agonists CI-977, 
U69,593, U50,488, EKC,  Mr2034 and bremazocine,  the 
mu  agonist  morphine  and the delta agonist  BW-373U86 
are displayed in Figs 1-3. All eight compounds  produced  
a dose-dependent  and complete suppression of  writhing. 
Tables 1 and 2 show the Aso values for each drug adminis- 
tered alone. The relative potencies of the kappa  agonists 
were bremazocine >_ CI-977 >_ Mr2034 > E K C  > 
U69,593 > U50,488. Morphine  was slightly more  potent  
than U50,488, and BW-373U86 was slightly less potent  
than U50,488. 
Time course of  the antagonist effects of  nor-BNI 
Figure 1 shows the time course of the antagonism of 
CI-977 by 32 mg/kg  nor-BNI,  and Table 1 shows the Aso 
values for CI-977 at the various times after n o r -BNI  
pretreatment.  One-hour  pretreatment  with 32 mg/kg  nor-  
BNI  produced a rightward, parallel shift in the CI-977 
dose-effect curve and a 2.9-fold increase in the As0. After 
a 4-h pretreatment  with 32 mg/kg nor -BNI ,  the Aso for 
CI-977 was increased 12-fold. Longer  pretreatment  times 
of  up to 28 days produced antagonis t  effects that  were 
similar to the antagonism observed after the 4-h pretreat- 
merit (dose ratios ranged f rom 8 to t9). Fol lowing a 56- 
day pretreatment  with nor-BNI,  the Aso for CI-977 was 
not  significantly different f rom the control  A~o for CI-977. 
Figure 2 shows the time course of  the antagonism of 
morphine  and BW-373U86 by 32 mg/kg  nor-BNI,  and 
Table 1 shows the Aso values for morph ine  and BW- 
373U86 at the various times after no r -BNI  pretreatment.  
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Fig. 1. Time course of the antagonist effects of 32 mg/kg nor-BNI in 
combination with the kappa agonist CI-977. Abscissa in this and all 
subsequent graphs: dose agonist in mg/kg (log scale). Ordinate in this 
and all subsequent graphs: % of control number of writhes per 
mouse. This figure shows the effects of nor-BNI administered 1 h, 
4 h, 4 weeks and 8 weeks prior to administration of CI-977. Each 
point in this and all subsequent graphs represents the mean data 
from 5-6 mice. II, CI-977 alone; [], + nor-BNI (1 h ptt); © + nor- 
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Fig, 2, Time course of the antagonist effects of 32 mg/kg nor-BNI 
administered 1 and 24 h prior to the administration of the mu 
agonist morphine (A) or the delta agonist BW-373U86 (B). l ,  
agonist alone, ~ ,  + nor-BNI (32 mg/kg-1 h ptt); ©, + nor-BNI 
(32 mg/kg-24 h ptt) 
with 32 mg/kg nor-BNI significantly affected the BW- 
373U86 dose-effect curve. 
Selectivity of the kappa antagonist effects of" nor-BNI 
Figure 3 shows the effects of CI-977, U50,488, U69,593, 
bremazocine, EKC and Mr2034 alone and in combination 
with 3.2, 10 and 32 mg/kg nor-BNI given 24 h previously. 
Table 2 shows the Aso values for each agonist alone and 
following nor-BNI pretreatment. Nor-BNI produced par- 
allel rightward shifts and significant increases in Aso 
values for all six kappa agonists; however, the pattern of 
antagonism differed across agonists. A dose of 3.2 mg/kg 
nor-BNI produced rightward shifts and increases in agon- 
ist Aso values of comparable magnitude for all six agon- 
ists, with dose ratios ranging from a low of 1.6 for EKC to 
a high of 3.8 for bremazocine. The magnitude of the 
increase in Aso value produced by 3.2 mg/kg nor-BNI was 
statistically significant for every agonist except EKC. In 
contrast to the similar effects produced by 3.2 mg/kg nor- 
BNI, the magnitude of the rightward shifts obtained with 
higher doses of nor-BNI differed dramatically across the 
different agonists. For example, 32 mg/kg nor-BNI produ- 
ced a 73-fold increase in the bremazocine A~o, but only 
a 3.8-fold increase in the Mr2034 Aso. Thus, although 
each of these agonists displayed a similar sensitivity to the 
antagonist effect of the low dose of nor-BNI (3.2 mg/kg), 
there was considerable variation in the ability of higher 
doses of nor-BNI (10 and 32 mg/kg) to produce additional 
rightward shifts in these agonist dose-effect curves. 
One-hour pretreatment with 32 mg/kg nor-BNI also pro- 
duced a parallel rightward shift in the dose-effect curve for 
morphine and a small but significant 2.2-fold increase in 
the morphine Aso. Twenty-four hour pretreatment with 
nor-BNI produced less of a shift in the morphine dose- 
effect curve, and the Aso for morphine no longer differed 
significantly from its baseline value (Horan et al. 1991; 
Endoh et al. t992). Neither 1-h nor 24-h pretreatment 
Antagonist effects of 13-FNA 
Table 3 compares the effects of 24-h pretreatment with 1) 
32mg/kg nor-BNI, 2) 32mg/kg /?-FNA or 3) nor- 
BNI +/~-FNA on dose-effect curves for CI-977, U69,593, 
BW-373U86, morphine, EKC and Mr2034. Pretreatment 
with nor-BNI produced a significant increase in the Asos 
for CI-977 and U69,593, but pretreatment with /3-FNA 
Table 1. Aso values in mg/kg and dose 
ratios for the kappa agonist CI-977, the mu 
agonist morphine and the delta agonist 
BW-373U86 alone and at various times 
after the administration of 32 mg/kg nor- 
BNI. The 95% confidence limits of the As0 
v~I~es--~re g[Veh- iii-par-entheses 
Nor-BNI 
Agonist Pretreatment time Aso (95% CL) Dose ratio 
CI-977 Alone 0.024 (0.018-0.03 i) - 
1 h 0.070 (0.045-0.11)* 2.9 
4 h 0.28 (0.18±0.44) * 12 
24 h 0.20 (0.12--0.33)* 8.3 
4 days 0.45 (0.33-0.68)* 19 
7 days 0.37 (0.30-0.45)* 15 
28 days 0.20 (0,12-0.32)* 8.0 
56 days 0.038 (0.027-0.053) 1.6 
Morphine Alone 0.55 (0.40-0.77) - 
1 h 1.2 (0.85-1.6)* 2.2 
24 h 1,1 (0.71-1.7) 2.0 
BW-373U86 Alone 3.7 (2.4-5,8) - 
1 h 5.2 (3.2-8,4) 1.4 
24 h 5.4 (3.0 9.9) 1,5 
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Fig. 3. Antagonist effects of 3.2, 10 and 32 mg/kg nor-BNI adminis- 
tered 24 h prior to the administration of the arylacetamide kappa 
agonists CI-977 (A), U69,593 (B) and U50,488 (C) and the ben- 
0.1 1 3.2 
Dose E K C  ( m g / k g )  
F 
0.01 0.1 0.32 
Dose M r 2 0 3 4  ( m g / k g )  
zomorphan kappa agonists bremazocine (D), EKC (E) and Mr2034 
(F). II, agonist alone; EI + nor-BNI (3.2 mg/kg); ©, + nor-BNI 
(I0 mg/kg); ~, + nor-BNI (32 mg/kg) 
had no effect, and pretreatment with nor-BNI + fl-FNA 
was no more effective that nor-BNI alone. For morphine, 
pretreatment with fl-FNA produced a significant increase 
in the Aso, but prior administration of nor-BNI had no 
effect, and pretreatment with nor-BNI + fl-FNA was no 
more effective than pretreatment with fl-,FNA alone. None 
of the nor-BNI or fl-FNA pretreatments had any affect on 
the Aso for BW-373U86. 
In contrast to the selective effects of nor-BNI 
and fl-FNA on CI-977, U69,593, morphine and BW- 
373U86, both nor-BNI and fl-FNA antagonist effects 
on Mr2034 and EKC. For Mr2034, the pretreatment 
with nor-BNI alone and fl-FNA alone produced signifi- 
cant increases in the Aso for Mr2034. Furthermore, 
pretreatment with nor-BNI + fl-FNA produced a greater 
increase in the Aso for Mr2034 and did either anta- 
gonist alone. For EKC, pretreatment with nor-BNI alone 
produced a significant increase in the Aso, whereas 
pretreatment with fl-FNA alone was without effect. 
However, pretreatment with nor-BNI + fl-FNA produ- 
ced a larger increase in the Aso for EKC than did 
nor-BNI alone. 
Discuss ion  
The kappa opioid agonists CI-977, U69,593, U50,488, 
bremazocine, EKC and Mr2034 as well as the mu-selec- 
five agonist morphine and the delta against BW-373U86, 
were fully effective in the writhing assay, each producing 
a dose-dependent suppression of the writhing response. 
The order of potency of the kappa agonists was: 
bremazocine > CI-977 > Mr2034 > EKC > U69,593 > 
U50,488. Morphine was slightly more potent than 
U50,488, and BW-373U86 less potent than U50,488. Pre- 
vious studies have reported similar relative potencies for 
these compounds in producing antinociception in the 
mouse acetic acid-induced writhing assay as well as in 
other procedures in mice and rats (Leander 1984; Hayes 
and Kelly 1987a; Hunter et al. 1990; Comer 1992). 
In the present study, nor-BNI produced kappa antag- 
onist effects with slow onset and extremely long duration 
of action (on the order of weeks). In addition, nor-BNI 
produced small mu antagonist effects which were signifi- 
cant at 1 h (Endoh et al. 1992). Nor-BNI did not antagon- 
ize the antinociceptive effects of BW-373U86 after either 
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Table 2. Aso values in mg/kg and dose 
ratios for CI-977, U50,488, U69,593, 
bremazocine, EKC and Mr2034 alone and 
24 h after pretreatment with 3.2, I0 or 
32 mg/kg nor-BNI. The 95% confidence 
limits of the A5o values are given in 
parentheses 
Dose nor-BNI 
Agonist (mg/kg) Aso (95% eL) Dose ratio 
CI-977 Alone 0.024 (0.018-0.031) - 
3.2 0.053 (0.045-0.62)* 2.2 
10 0.056 (0.026-0.12) 2.3 
32 0.20 (0.12-0.33)* 8.3 
U50,488 Alone 1.8 (1.0-3. t) - 
3.2 6.1 (5.1--7.4)* 3.4 
10 12 (7.9-19)* 6.7 
32 52 (35-80)* 29 
U69,593 Alone 0.24 (0.17-0.35) - 
3.2 0.63 (0.48-0.83)* 2.6 
10 2.3 (1.8-2.9)* 9.6 
32 5.1 (3.4-7.9)* 21 
Bremazocine Alone 0.012 (0.0090-0.015) - 
3.2 0.046 (0.022 0.097)* 3.8 
10 0.13 (0.080-0.22)* 11 
32 0.88 (0.60-1.3)* 73 
EKC Alone 0.14 (0.078-0.24) - 
3.2 0.22 (0.16-0.29) 1.6 
10 0.51 (0.42-0.62)* 3.6 
32 0.67 (0.540.82)* 4.8 
Mr2034 Alone 0.026 (0.016-0.042) - 
3.2 0.068 (0.049-0.095)* 2.6 
10 0,11 (0.065~).17)* 4,2 
32 0.098 (0.077-0.12)* 3.8 
* Indicates Aso values significantly different from As0 value for agonist alone 
Table 3. As0 values in mg/kg for CI-977, U69,593, morphine, BW-373U86, Mr2034 and EKC alone and 24 h after pretreatment with 
32 mg/kg nor-BNI alone, 32 mg/kg fl-FNA alone or a combination of 32 mg/kg nor-BNI + 32 mg/kg fl-FNA. The 95% confidence limits of 
the Aso values are shown in parentheses 
Agonist Agonist alone ~ + nor-BNP + fl-FNA + nor-BNI and fl-FNA 
CI-977 0.024 (0.018-0.031) 0.20 (0.12 0.33)* 0.019 (0.015-0.024) 0.38 (0.25-0.58)* 
U69,593 0.24 (0.17-0.35) 5.1 (3.4-7.9)* 0.31 (0.24~).4t) 7.2 (4.5-11)* 
Morphine 0.61 (0.45-0.84) 1.1 (0.71-1.7) 4.0 (3.0-5.4)* 5.6 (4.4 7.1)* 
BW-373U86 3.7 (2.4-5.8) 5.4 (3.0-9.9) 2.5 (1.6 3.7) 7.3 (4.8-11) 
Mr2034 0.026 (0.0 t 6-0.042) 0.098 (0.077-0.012)* 0.11 (0.076 -0.16)* 1.0 (0.77-1.4)* 
EKC 0.14 (0.078 0.24) 0.67 (0.54 0.82)* 0.16 (0.12-0.21) 1.55 (1.2-2.1)*~, 
a Data taken from Table 2 
* Significantly different from agonist alone 
c, Combination significantly different from nor-BNI alone and fl-FNA alone 
1- or  24-h pretreatment  with nor-BNI.  BW-373U86 has 
been characterized as a novel, systemically-active, alkal- 
oid delta agonist whose antinociceptive effects are potent-  
ly and selectively antagonized by the delta antagonist  
naltrindole in the mouse writhing assay (Comer 1992). 
Thus our  finding that no r -BNI  pretreatment  failed to 
antagonize the antinociceptive effects of BW-373U86 sug- 
gests that  no r -BN I  did not  act as a delta receptor antag- 
onist in the dose range studied. 
This profile of no r -BNI  agrees with other studies that 
have characterized the time course and selectivity of the 
opioid antagonist  effects of  no r -BNI  administered by the 
same route of  administrat ion (SC; Takemori  et al. 1988a; 
Endoh  et al. 1992), as well as the ICV route of administra- 
tion (Takemori  etal .  1988a; Horan  etal .  1992). For  
example, Endoh  et al. (1992) found that the mu antagonist  
effects of  no r -BNI  (as evaluated against morphine)  peaked 
30-60 min after no r -BNI  administrat ion and were no 
longer detectable after 4 h, and at 24 h after its administra-  
tion, no r -BNI  displayed highly selective kappa  antagonist  
effects. Our  finding that  no r -BNI  did no t  antagonize BW- 
373U86 also agrees with other studies showing that  nor-  
BNI  is either ineffective as a delta antagonist  or  less potent  
as a delta antagonist  than as a kappa  antagonis t  (Birch 
et al. 1987; Takemori  et al. 1988a,b; H o r a n  et at. 1992). 
The present study extended this characterizat ion of 
no r -BNI  by examining in detail the antagonist  effects of 
no r -BNI  against a series of  arylacetamide and benzomor-  
phan  kappa  agonists and determining whether different 
kappa  agonists displayed differential sensitivity to antag- 
onism by nor-BNI.  These antagonism experiments were 
conducted 24 h after pretreatment  with nor-BNI.  Several 
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studies have indicated that, from several hours to several 
days after its administration, nor-BNI displays peak an- 
tagonist effects against several kappa agonists including 
CI-977 (present study), U50,488 (Endoh et al. 1992), 
U69,593 and bremazocine (Horan et al. 1991). This sug- 
gests that a 24 h pretreatment time should lie within the 
time of the peak antagonist effects of nor-BNI. Using this 
pretreatment time, all six kappa agonists were signifi- 
cantly antagonized by nor-BNI. Furthermore, the kappa 
agonists displayed similar sensitivity to antagonism by 
3.2 mg/kg nor-BNI after 24 h, with dose-effect curves for 
five of the six agonists being shifted to the right to a sim- 
ilar and statistically significant degree. Only the EKC 
dose-effect curve was not shifted to the right to a signifi- 
cant degree by 3.2 mg/kg nor-BNI, but the EKC dose- 
effect curve was shifted significantly in the presence of 10 
and 32 mg/kg nor-BNI. These findings suggest that at 
least some portion of the antinociceptive effects of CI-977, 
U50,488, U69,593, bremazocine, EKC and Mr2034 was 
mediated by a similar (nor-BNI sensitive) population of 
kappa opioid receptors. 
Despite these similarities however, the kappa agonists 
evaluated in the present study displayed dramatically dif- 
ferent sensitivity to the antagonist effects of doses of nor- 
BNI higher than 3.2 mg/kg. This difference becomes most 
evident when comparing the antagonist effects of nor-BNI 
against bremazocine and Mr2034. Pretreatment with 
3.2 mg/kg nor-BNI produced similar and significant right- 
ward shifts in the dose-effect curves of both bremazocine 
and Mr2034 as mentioned above (3.8-fold and 2.6-fold, 
respectively); however, the effect of pretreatment with 
32 mg/kg nor-BNI on the two agonist dose-effect curves 
differed widely: the bremazocine As0 was increased 73- 
fold relative to control, whereas the Aso for Mr2034 was 
increased only 3.8-fold relative to control. Thus, nor-BNI 
produced a dose-dependent antagonism of bremazocine, 
but the higher doses of nor-BNI in combination with 
Mr2034 were no more effective than the low dose of 
nor-BNI. 
These findings agree with other studies in rodents 
reporting that the effectiveness of nor-BNI as a kappa 
antagonist varies across kappa agonists (Takemori et al. 
1988a, b), and suggest that some kappa agonists are ca- 
pane of producing antinociceptive effects in the writhing 
assay in mice by acting at nor-BNI-insensitive receptors 
as well as at nor-BNI-sensitive receptors. The first and 
most likely possibility is that non-kappa receptors, parti- 
cularly mu opioid receptors, may have contributed to the 
antinociceptive effects of some of the kappa agonists test- 
ed in this study, namely EKC and Mr2034. Binding stud- 
ies have shown that Mr2034 and EKC each have high 
affinity for mu as well as kappa receptors (Wood et al. 
1981; Magnan et al. 1982; Hunter et al. 1990). In addition, 
functional studies have demonstrated that Mr2034 and 
EKC can function as mu agonists in rodents under some 
circumstances, indicating that they may have sufficient 
efficacy at mu receptors to produce mu agonist effects 
(Hayes et al. 1987b; Zimmerman et al. 1987). 
The hypothesis that mu-receptor activation contrib- 
uted to the antinociceptive effects of Mr2034 and EKC 
was tested in the present study using the mu-selective 
antagonist ~-FNA. A twenty-four hour pretreatment with 
both fl-FNA and nor-BNI was no more effective at antag- 
onizing the dose effect curves of morphine, BW-373U86, 
CI-977 or U69,593 than when either nor-BNI or ~-FNA 
was given alone. However, the nor-BNI and ~-FNA com- 
bination was considerably more effective antagonizing 
both Mr2034 and EKC than either antagonist was alone. 
In the case of Mr2034, both nor-BNI and/~-FNA when 
given alone produced about a 4-fold increase in its As0, 
but the combination of nor-BNI +/~-FNA increased the 
Mr2034 Aso by nearly 40-fold, suggesting that the anti- 
nociceptive effects of Mr2034 were mediated, at least in 
part, by mu opioid receptors. ~-FNA alone did not antag- 
onize EKC, suggesting that ordinarily the antinociceptive 
effects of EKC are not mediated by mu receptors. How- 
ever, pretreatment with both ]~-FNA and nor-BNI produ- 
ced a bigger increase in the Aso for EKC than nor-BNI 
alone, suggesting that once kappa receptors are blocked 
by nor-BNI, mu-receptor activation may contribute to the 
antinociceptive effects of EKC. 
In contrast to the low kappa selectivity of Mr2034 and 
EKC, the arylacetamides CI-977, U50,488 and U69,593 
display high affinity for kappa receptors and high selectiv- 
ity for kappa versus mu receptors (Lahti et al. 1985; 
Hunter et al. 1990). Bremazocine resembles the other ben- 
zomorphans Mr2034 and EKC in having high affinity for 
both kappa and mu receptors (Magnan et al. 1982; Hunter 
et al. 1990), but bremazocine has been reported to have 
very low efficacy at mu receptors and to function prim- 
arily as a mu antagonist (Yon Voigtlander et al. 1982; 
Petrillo et al. 1984; Corbett and Kosterlitz 1986; Negus 
et al. 1990), indicating that bremazocine is selectively effi- 
cacious at kappa versus mu receptors. Thus, the com- 
pounds most sensitive to nor-BNI antagonism--CI-977, 
U50,844, U69,593 and bremazocine--are all characterized 
by either selective affinity for, or selective efficacy at, 
kappa versus mu receptors. 
Coincident with the present study in mice, a study of 
similar design was conducted to examine the kappa antag- 
onist effects of nor-BNI in the warm-water tail-with- 
drawal procedure in rhesus monkeys (Butelman et al. 
1993), and it is of interest to compare the results of the two 
studies. In agreement with the present study, nor-BNI was 
shown to produce selective kappa antagonist effects for up 
to several weeks in rhesus monkeys. However, the sensi- 
tivity of various kappa agonists to antagonism by nor- 
BNI in mice differed markedly in rhesus monkeys. In the 
mice, as discussed above, nor-BNI was an effective antag- 
onist of all kappa agonists tested, and most effective 
against bremazocine. Conversely, in the monkeys nor- 
BNI was an effective antagonist of U50,488 and U69,593, 
producing a half-log or greater shift in their dose-effect 
curves, but this same dose had no effect on the dose-effect 
curves for CI-977, bremazocine, EKC or Mr2033 (the 
racemate of Mr2034). Thus, whereas differential antagon- 
ism by nor-BNI of different kappa agonists in mice can be 
attributed largely to the potential for these compounds to 
act as mu agonists, the differential antagonism of different 
kappa agonists in rhesus monkeys cannot be so readily 
explained. The conclusion drawn from the experiments in 
monkeys was that different kappa agonists produced their 
antinociceptive effects by acting on different kappa recep- 
tor subtypes, and that nor-BNI distinguished between 
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these subtypes. The finding that the profile of antagonist  
activity by nor -BNI  differed in mice and rhesus monkeys  
is consistent with observations of  dramatic  species differ- 
ences in kappa  receptor binding (Robson et al. 1985; Man-  
sour et al. 1988; Sharif et al. 1990). For  example, it has 
been reported that  both  the relative p ropor t ion  of  kappa  
receptors to mu and delta receptors and the absolute 
density of  kappa  receptors are much  tess in mice and rats 
than in several other mammal ian  species, including hu- 
mans (Mansour  et al. 1988). 
In summary,  the present study found that  no r -BNI  
produced long-lasting and selective kappa  antagonist  
effects in mice. Furthermore,  the present study identified 
differences in the sensitivity of six kappa  agonists to 
antagonism by nor-BNI.  All kappa  agonists tested were 
significantly antagonized by lower doses of  nor-BNI,  
indicating that  at least some componen t  of the effect of  
each of  these agonists was mediated by pharmaco-  
logically similar, nor-BNI-sensit ive kappa  opioid recep- 
tors. However,  these kappa  agonists were markedly differ- 
ent in their sensitivity to higher doses of nor-BNI.  This 
finding, together with results of  the antagonism studies 
with fi-FNA, suggests that  in mice, the differential effects 
of no r -BNI  on kappa  agonists is based on the efficacy of 
the agonist  at non-kappa  (probably mu) sites rather than 
on the selectivity of no r -BNI  for subtypes of the kappa  
receptor. 
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